StreetInsider.com News Articles

StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 29 Sep 2026 07:30:39 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Optimi Health adds finance executive Melanie Pump to its board http://www.streetinsider.com/Board+Changes/Optimi+Health+adds+finance+executive+Melanie+Pump+to+its+board/27117427.html <p>Optimi Health Corp. (NASDAQ: OPTH, CSE: OPTI) announced the appointment of Melanie Pump to its Board of Directors, according to a company press release.</p> <p>Pump has more than 25 years of experience in finance across technology, digital infrastructure, software, fintech, and emerging growth companies. She currently serves as Chief Financial Officer of Qu Data Centres and sits on the Board of Directors of Mobio Technologies Inc. (TSXV: MBO). She previously served as a director of BTCS Inc.</p> <p>Dane Stevens, Optimi's Chief Executive Officer and Co-Founder, said Pump's "extensive financial leadership experience across technology-driven and emerging growth companies, together with her public company http://www.streetinsider.com/Board+Changes/Optimi+Health+adds+finance+executive+Melanie+Pump+to+its+board/27117427.html Tue, 29 Sep 2026 07:30:39 -0400 MBO OPTH OPTI Optimi Health adds finance executive Melanie Pump to its board http://www.streetinsider.com/Board+Changes/Optimi+Health+adds+finance+executive+Melanie+Pump+to+its+board/27117427.html <p>Optimi Health Corp. (NASDAQ: OPTH, CSE: OPTI) announced the appointment of Melanie Pump to its Board of Directors, according to a company press release.</p> <p>Pump has more than 25 years of experience in finance across technology, digital infrastructure, software, fintech, and emerging growth companies. She currently serves as Chief Financial Officer of Qu Data Centres and sits on the Board of Directors of Mobio Technologies Inc. (TSXV: MBO). She previously served as a director of BTCS Inc.</p> <p>Dane Stevens, Optimi's Chief Executive Officer and Co-Founder, said Pump's "extensive financial leadership experience across technology-driven and emerging growth companies, together with her public company http://www.streetinsider.com/Board+Changes/Optimi+Health+adds+finance+executive+Melanie+Pump+to+its+board/27117427.html Tue, 29 Sep 2026 07:30:39 -0400 MBO OPTH OPTI Optimi Health adds finance executive Melanie Pump to its board http://www.streetinsider.com/Board+Changes/Optimi+Health+adds+finance+executive+Melanie+Pump+to+its+board/27117427.html <p>Optimi Health Corp. (NASDAQ: OPTH, CSE: OPTI) announced the appointment of Melanie Pump to its Board of Directors, according to a company press release.</p> <p>Pump has more than 25 years of experience in finance across technology, digital infrastructure, software, fintech, and emerging growth companies. She currently serves as Chief Financial Officer of Qu Data Centres and sits on the Board of Directors of Mobio Technologies Inc. (TSXV: MBO). She previously served as a director of BTCS Inc.</p> <p>Dane Stevens, Optimi's Chief Executive Officer and Co-Founder, said Pump's "extensive financial leadership experience across technology-driven and emerging growth companies, together with her public company http://www.streetinsider.com/Board+Changes/Optimi+Health+adds+finance+executive+Melanie+Pump+to+its+board/27117427.html Tue, 29 Sep 2026 07:30:39 -0400 MBO OPTH OPTI Optimi Health Appoints Melanie Pump to Board of Directors http://www.streetinsider.com/Press+Releases/Optimi+Health+Appoints+Melanie+Pump+to+Board+of+Directors/27117419.html <p align="justify">VANCOUVER, British Columbia, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("<strong>Optimi</strong>" or the “<strong>Company</strong>"), a commercial-stage manufacturer and clinical-stage developer of regulated psychedelic drug products, today announced the appointment of Melanie Pump to its Board of Directors (the "<strong>Board</strong>").</p> <p align="justify">Ms. Pump is a seasoned finance executive with more than 25 years of experience across technology, digital infrastructure, software, fintech and emerging growth companies. She currently serves as Chief Financial Officer of Qu Data Centres.</p> <p align="justify"><em>"We are pleased to welcome Melanie to Optimi’s Board,"</em> said Dane http://www.streetinsider.com/Press+Releases/Optimi+Health+Appoints+Melanie+Pump+to+Board+of+Directors/27117419.html Tue, 29 Sep 2026 07:30:00 -0400 MBO OPTH OPTI Optimi Health Appoints Melanie Pump to Board of Directors http://www.streetinsider.com/Globe+Newswire/Optimi+Health+Appoints+Melanie+Pump+to+Board+of+Directors/27117419.html <p align="justify">VANCOUVER, British Columbia, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("<strong>Optimi</strong>" or the “<strong>Company</strong>"), a commercial-stage manufacturer and clinical-stage developer of regulated psychedelic drug products, today announced the appointment of Melanie Pump to its Board of Directors (the "<strong>Board</strong>").</p> <p align="justify">Ms. Pump is a seasoned finance executive with more than 25 years of experience across technology, digital infrastructure, software, fintech and emerging growth companies. She currently serves as Chief Financial Officer of Qu Data Centres.</p> <p align="justify"><em>"We are pleased to welcome Melanie to Optimi’s Board,"</em> said Dane http://www.streetinsider.com/Globe+Newswire/Optimi+Health+Appoints+Melanie+Pump+to+Board+of+Directors/27117419.html Tue, 29 Sep 2026 07:30:00 -0400 MBO OPTH OPTI Optimi Health Appoints Melanie Pump to Board of Directors http://www.streetinsider.com/Press+Releases/Optimi+Health+Appoints+Melanie+Pump+to+Board+of+Directors/27117419.html <p align="justify">VANCOUVER, British Columbia, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("<strong>Optimi</strong>" or the “<strong>Company</strong>"), a commercial-stage manufacturer and clinical-stage developer of regulated psychedelic drug products, today announced the appointment of Melanie Pump to its Board of Directors (the "<strong>Board</strong>").</p> <p align="justify">Ms. Pump is a seasoned finance executive with more than 25 years of experience across technology, digital infrastructure, software, fintech and emerging growth companies. She currently serves as Chief Financial Officer of Qu Data Centres.</p> <p align="justify"><em>"We are pleased to welcome Melanie to Optimi’s Board,"</em> said Dane http://www.streetinsider.com/Press+Releases/Optimi+Health+Appoints+Melanie+Pump+to+Board+of+Directors/27117419.html Tue, 29 Sep 2026 07:30:00 -0400 MBO OPTH OPTI Optimi Health Appoints Melanie Pump to Board of Directors http://www.streetinsider.com/Globe+Newswire/Optimi+Health+Appoints+Melanie+Pump+to+Board+of+Directors/27117419.html <p align="justify">VANCOUVER, British Columbia, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("<strong>Optimi</strong>" or the “<strong>Company</strong>"), a commercial-stage manufacturer and clinical-stage developer of regulated psychedelic drug products, today announced the appointment of Melanie Pump to its Board of Directors (the "<strong>Board</strong>").</p> <p align="justify">Ms. Pump is a seasoned finance executive with more than 25 years of experience across technology, digital infrastructure, software, fintech and emerging growth companies. She currently serves as Chief Financial Officer of Qu Data Centres.</p> <p align="justify"><em>"We are pleased to welcome Melanie to Optimi’s Board,"</em> said Dane http://www.streetinsider.com/Globe+Newswire/Optimi+Health+Appoints+Melanie+Pump+to+Board+of+Directors/27117419.html Tue, 29 Sep 2026 07:30:00 -0400 MBO OPTH OPTI Optimi Health Appoints Melanie Pump to Board of Directors http://www.streetinsider.com/Press+Releases/Optimi+Health+Appoints+Melanie+Pump+to+Board+of+Directors/27117419.html <p align="justify">VANCOUVER, British Columbia, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("<strong>Optimi</strong>" or the “<strong>Company</strong>"), a commercial-stage manufacturer and clinical-stage developer of regulated psychedelic drug products, today announced the appointment of Melanie Pump to its Board of Directors (the "<strong>Board</strong>").</p> <p align="justify">Ms. Pump is a seasoned finance executive with more than 25 years of experience across technology, digital infrastructure, software, fintech and emerging growth companies. She currently serves as Chief Financial Officer of Qu Data Centres.</p> <p align="justify"><em>"We are pleased to welcome Melanie to Optimi’s Board,"</em> said Dane http://www.streetinsider.com/Press+Releases/Optimi+Health+Appoints+Melanie+Pump+to+Board+of+Directors/27117419.html Tue, 29 Sep 2026 07:30:00 -0400 MBO OPTH OPTI Optimi Health Appoints Melanie Pump to Board of Directors http://www.streetinsider.com/Globe+Newswire/Optimi+Health+Appoints+Melanie+Pump+to+Board+of+Directors/27117419.html <p align="justify">VANCOUVER, British Columbia, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("<strong>Optimi</strong>" or the “<strong>Company</strong>"), a commercial-stage manufacturer and clinical-stage developer of regulated psychedelic drug products, today announced the appointment of Melanie Pump to its Board of Directors (the "<strong>Board</strong>").</p> <p align="justify">Ms. Pump is a seasoned finance executive with more than 25 years of experience across technology, digital infrastructure, software, fintech and emerging growth companies. She currently serves as Chief Financial Officer of Qu Data Centres.</p> <p align="justify"><em>"We are pleased to welcome Melanie to Optimi’s Board,"</em> said Dane http://www.streetinsider.com/Globe+Newswire/Optimi+Health+Appoints+Melanie+Pump+to+Board+of+Directors/27117419.html Tue, 29 Sep 2026 07:30:00 -0400 MBO OPTH OPTI Optimi Health completes psilocybin batch for trial and Australia supply http://www.streetinsider.com/FDA/Optimi+Health+completes+psilocybin+batch+for+trial+and+Australia+supply/27094133.html <p>Optimi Health Corp. (NASDAQ: OPTH, CSE: OPTI) announced the completion and quality release of a production batch of 5mg naturally derived psilocybin capsules, manufactured at its cGMP facility in Princeton, British Columbia, under a Health Canada Drug Establishment Licence.</p> <p>The batch will serve two purposes: supplying a Health Canada-authorized Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder (MDD), and fulfilling commercial orders from licensed clinics in Australia.</p> <p>The Phase 2 trial is a multisite, open-label study of up to 200 participants, each receiving a single supervised dose. Patient dosing is expected to be completed by the end of 2027. http://www.streetinsider.com/FDA/Optimi+Health+completes+psilocybin+batch+for+trial+and+Australia+supply/27094133.html Wed, 23 Sep 2026 09:00:58 -0400 OPTH OPTI Optimi Health completes psilocybin batch for trial and Australia supply http://www.streetinsider.com/FDA/Optimi+Health+completes+psilocybin+batch+for+trial+and+Australia+supply/27094133.html <p>Optimi Health Corp. (NASDAQ: OPTH, CSE: OPTI) announced the completion and quality release of a production batch of 5mg naturally derived psilocybin capsules, manufactured at its cGMP facility in Princeton, British Columbia, under a Health Canada Drug Establishment Licence.</p> <p>The batch will serve two purposes: supplying a Health Canada-authorized Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder (MDD), and fulfilling commercial orders from licensed clinics in Australia.</p> <p>The Phase 2 trial is a multisite, open-label study of up to 200 participants, each receiving a single supervised dose. Patient dosing is expected to be completed by the end of 2027. http://www.streetinsider.com/FDA/Optimi+Health+completes+psilocybin+batch+for+trial+and+Australia+supply/27094133.html Wed, 23 Sep 2026 09:00:58 -0400 OPTH OPTI Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+Psilocybin+Production+for+Health+Canada-Approved+Phase+2+MDD+Trial+and+Commercial+TRD+Supply/27094048.html <p align="justify">VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("<strong>Optimi</strong>" or the "<strong>Company</strong>"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion and quality release of a production batch of 5mg naturally derived psilocybin capsules, manufactured end to end at the Company’s cGMP facility in Princeton, British Columbia, under a Health Canada Drug Establishment Licence. The batch will supply the recently <a target="_blank" href="https://www.globenewswire.com/Tracker?data=aA7s195XjjLCWXzixPW2USf9C2jv9TJxgqOSv3VdyPVgVQiQc575-a6tAzqnLR5b7CsMQWrA4Lpzr9_luKw2HBkthO39Jz6CBxnvZ5holC8MCR9KIyV2IWMg6ChDrNjYYyUCHVWA-XbpKmjQk50vlXYUqCCwrw0uwjq0zuP17f0-_VjcOt-XHA5x1d3uw-7Qdb9K9EBa3Po43H_zMfq4I91M1FGO-uf7HauGi8I4kaajgH9dkTtF4ydPXExoP3BgbdjNkeS2-4HUQEaSOYXpmw==" rel="nofollow" target="_blank">announced Phase 2 clinical trial of psilocybin-assisted therapy</a> evaluating psilocybin-assisted therapy in the treatment of major depressive disorder (“MDD”) http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+Psilocybin+Production+for+Health+Canada-Approved+Phase+2+MDD+Trial+and+Commercial+TRD+Supply/27094048.html Wed, 23 Sep 2026 09:00:00 -0400 OPTH OPTI Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply http://www.streetinsider.com/Globe+Newswire/Optimi+Health+Completes+Psilocybin+Production+for+Health+Canada-Approved+Phase+2+MDD+Trial+and+Commercial+TRD+Supply/27094048.html <p align="justify">VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("<strong>Optimi</strong>" or the "<strong>Company</strong>"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion and quality release of a production batch of 5mg naturally derived psilocybin capsules, manufactured end to end at the Company’s cGMP facility in Princeton, British Columbia, under a Health Canada Drug Establishment Licence. The batch will supply the recently <a target="_blank" href="https://www.globenewswire.com/Tracker?data=aA7s195XjjLCWXzixPW2USf9C2jv9TJxgqOSv3VdyPVgVQiQc575-a6tAzqnLR5b7CsMQWrA4Lpzr9_luKw2HBkthO39Jz6CBxnvZ5holC8MCR9KIyV2IWMg6ChDrNjYYyUCHVWA-XbpKmjQk50vlXYUqCCwrw0uwjq0zuP17f0-_VjcOt-XHA5x1d3uw-7Qdb9K9EBa3Po43H_zMfq4I91M1FGO-uf7HauGi8I4kaajgH9dkTtF4ydPXExoP3BgbdjNkeS2-4HUQEaSOYXpmw==" rel="nofollow" target="_blank">announced Phase 2 clinical trial of psilocybin-assisted therapy</a> evaluating psilocybin-assisted therapy in the treatment of major depressive disorder (“MDD”) http://www.streetinsider.com/Globe+Newswire/Optimi+Health+Completes+Psilocybin+Production+for+Health+Canada-Approved+Phase+2+MDD+Trial+and+Commercial+TRD+Supply/27094048.html Wed, 23 Sep 2026 09:00:00 -0400 OPTH OPTI Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+Psilocybin+Production+for+Health+Canada-Approved+Phase+2+MDD+Trial+and+Commercial+TRD+Supply/27094048.html <p align="justify">VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("<strong>Optimi</strong>" or the "<strong>Company</strong>"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion and quality release of a production batch of 5mg naturally derived psilocybin capsules, manufactured end to end at the Company’s cGMP facility in Princeton, British Columbia, under a Health Canada Drug Establishment Licence. The batch will supply the recently <a target="_blank" href="https://www.globenewswire.com/Tracker?data=aA7s195XjjLCWXzixPW2USf9C2jv9TJxgqOSv3VdyPVgVQiQc575-a6tAzqnLR5b7CsMQWrA4Lpzr9_luKw2HBkthO39Jz6CBxnvZ5holC8MCR9KIyV2IWMg6ChDrNjYYyUCHVWA-XbpKmjQk50vlXYUqCCwrw0uwjq0zuP17f0-_VjcOt-XHA5x1d3uw-7Qdb9K9EBa3Po43H_zMfq4I91M1FGO-uf7HauGi8I4kaajgH9dkTtF4ydPXExoP3BgbdjNkeS2-4HUQEaSOYXpmw==" rel="nofollow" target="_blank">announced Phase 2 clinical trial of psilocybin-assisted therapy</a> evaluating psilocybin-assisted therapy in the treatment of major depressive disorder (“MDD”) http://www.streetinsider.com/Press+Releases/Optimi+Health+Completes+Psilocybin+Production+for+Health+Canada-Approved+Phase+2+MDD+Trial+and+Commercial+TRD+Supply/27094048.html Wed, 23 Sep 2026 09:00:00 -0400 OPTH OPTI Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply http://www.streetinsider.com/Globe+Newswire/Optimi+Health+Completes+Psilocybin+Production+for+Health+Canada-Approved+Phase+2+MDD+Trial+and+Commercial+TRD+Supply/27094048.html <p align="justify">VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("<strong>Optimi</strong>" or the "<strong>Company</strong>"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion and quality release of a production batch of 5mg naturally derived psilocybin capsules, manufactured end to end at the Company’s cGMP facility in Princeton, British Columbia, under a Health Canada Drug Establishment Licence. The batch will supply the recently <a target="_blank" href="https://www.globenewswire.com/Tracker?data=aA7s195XjjLCWXzixPW2USf9C2jv9TJxgqOSv3VdyPVgVQiQc575-a6tAzqnLR5b7CsMQWrA4Lpzr9_luKw2HBkthO39Jz6CBxnvZ5holC8MCR9KIyV2IWMg6ChDrNjYYyUCHVWA-XbpKmjQk50vlXYUqCCwrw0uwjq0zuP17f0-_VjcOt-XHA5x1d3uw-7Qdb9K9EBa3Po43H_zMfq4I91M1FGO-uf7HauGi8I4kaajgH9dkTtF4ydPXExoP3BgbdjNkeS2-4HUQEaSOYXpmw==" rel="nofollow" target="_blank">announced Phase 2 clinical trial of psilocybin-assisted therapy</a> evaluating psilocybin-assisted therapy in the treatment of major depressive disorder (“MDD”) http://www.streetinsider.com/Globe+Newswire/Optimi+Health+Completes+Psilocybin+Production+for+Health+Canada-Approved+Phase+2+MDD+Trial+and+Commercial+TRD+Supply/27094048.html Wed, 23 Sep 2026 09:00:00 -0400 OPTH OPTI Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer http://www.streetinsider.com/Press+Releases/Optimi+Health+Appoints+Dr.+Michael+Blough+as+Chief+Clinical+Development+Officer/27088591.html <p align="justify">VANCOUVER, British Columbia, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("<strong>Optimi</strong>" or the "<strong>Company</strong>"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the appointment of Michael Blough, Ph.D., as Chief Clinical Development Officer.</p> <p align="justify">Dr. Blough has significant experience leading Health Canada-authorized clinical trials and has worked with Optimi on clinical trial applications since 2022. In this newly created position, he will oversee Optimi’s clinical development strategy and related operations. This includes the Company’s planned Phase 2 clinical trial evaluating naturally derived psilocybin-assisted psychotherapy to http://www.streetinsider.com/Press+Releases/Optimi+Health+Appoints+Dr.+Michael+Blough+as+Chief+Clinical+Development+Officer/27088591.html Tue, 22 Sep 2026 09:00:00 -0400 OPTH OPTI Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer http://www.streetinsider.com/Globe+Newswire/Optimi+Health+Appoints+Dr.+Michael+Blough+as+Chief+Clinical+Development+Officer/27088591.html <p align="justify">VANCOUVER, British Columbia, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("<strong>Optimi</strong>" or the "<strong>Company</strong>"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the appointment of Michael Blough, Ph.D., as Chief Clinical Development Officer.</p> <p align="justify">Dr. Blough has significant experience leading Health Canada-authorized clinical trials and has worked with Optimi on clinical trial applications since 2022. In this newly created position, he will oversee Optimi’s clinical development strategy and related operations. This includes the Company’s planned Phase 2 clinical trial evaluating naturally derived psilocybin-assisted psychotherapy to http://www.streetinsider.com/Globe+Newswire/Optimi+Health+Appoints+Dr.+Michael+Blough+as+Chief+Clinical+Development+Officer/27088591.html Tue, 22 Sep 2026 09:00:00 -0400 OPTH OPTI Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer http://www.streetinsider.com/Press+Releases/Optimi+Health+Appoints+Dr.+Michael+Blough+as+Chief+Clinical+Development+Officer/27088591.html <p align="justify">VANCOUVER, British Columbia, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("<strong>Optimi</strong>" or the "<strong>Company</strong>"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the appointment of Michael Blough, Ph.D., as Chief Clinical Development Officer.</p> <p align="justify">Dr. Blough has significant experience leading Health Canada-authorized clinical trials and has worked with Optimi on clinical trial applications since 2022. In this newly created position, he will oversee Optimi’s clinical development strategy and related operations. This includes the Company’s planned Phase 2 clinical trial evaluating naturally derived psilocybin-assisted psychotherapy to http://www.streetinsider.com/Press+Releases/Optimi+Health+Appoints+Dr.+Michael+Blough+as+Chief+Clinical+Development+Officer/27088591.html Tue, 22 Sep 2026 09:00:00 -0400 OPTH OPTI Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer http://www.streetinsider.com/Globe+Newswire/Optimi+Health+Appoints+Dr.+Michael+Blough+as+Chief+Clinical+Development+Officer/27088591.html <p align="justify">VANCOUVER, British Columbia, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("<strong>Optimi</strong>" or the "<strong>Company</strong>"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the appointment of Michael Blough, Ph.D., as Chief Clinical Development Officer.</p> <p align="justify">Dr. Blough has significant experience leading Health Canada-authorized clinical trials and has worked with Optimi on clinical trial applications since 2022. In this newly created position, he will oversee Optimi’s clinical development strategy and related operations. This includes the Company’s planned Phase 2 clinical trial evaluating naturally derived psilocybin-assisted psychotherapy to http://www.streetinsider.com/Globe+Newswire/Optimi+Health+Appoints+Dr.+Michael+Blough+as+Chief+Clinical+Development+Officer/27088591.html Tue, 22 Sep 2026 09:00:00 -0400 OPTH OPTI Optimi Health plans Phase 3 MDMA-assisted therapy trial for PTSD http://www.streetinsider.com/FDA/Optimi+Health+plans+Phase+3+MDMA-assisted+therapy+trial+for+PTSD/27067803.html <p>Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) announced plans to initiate a Health Canada-authorized Phase 3 clinical trial evaluating MDMA-assisted therapy for post-traumatic stress disorder, with the trial expected to begin in 2027.</p> <p>The trial is designed to enroll up to 100 participants across multiple sites in Canada. Enrollment will focus on veterans and current or former frontline workers, including military personnel, police, paramedics, firefighters, and healthcare workers.</p> <p>Participants will receive the company's synthetic MDMA HCl in two dosage formats during two supervised sessions combined with psychotherapy, spaced several weeks apart. The primary efficacy endpoint will be change in the Clinician-Administered PTSD http://www.streetinsider.com/FDA/Optimi+Health+plans+Phase+3+MDMA-assisted+therapy+trial+for+PTSD/27067803.html Wed, 16 Sep 2026 08:25:15 -0400 OPTH OPTI Optimi Health plans Phase 3 MDMA-assisted therapy trial for PTSD http://www.streetinsider.com/FDA/Optimi+Health+plans+Phase+3+MDMA-assisted+therapy+trial+for+PTSD/27067803.html <p>Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) announced plans to initiate a Health Canada-authorized Phase 3 clinical trial evaluating MDMA-assisted therapy for post-traumatic stress disorder, with the trial expected to begin in 2027.</p> <p>The trial is designed to enroll up to 100 participants across multiple sites in Canada. Enrollment will focus on veterans and current or former frontline workers, including military personnel, police, paramedics, firefighters, and healthcare workers.</p> <p>Participants will receive the company's synthetic MDMA HCl in two dosage formats during two supervised sessions combined with psychotherapy, spaced several weeks apart. The primary efficacy endpoint will be change in the Clinician-Administered PTSD http://www.streetinsider.com/FDA/Optimi+Health+plans+Phase+3+MDMA-assisted+therapy+trial+for+PTSD/27067803.html Wed, 16 Sep 2026 08:25:15 -0400 OPTH OPTI Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder http://www.streetinsider.com/Press+Releases/Optimi+Health+Expands+Clinical+Program+with+Phase+3+Trial+Evaluating+MDMA-Assisted+Therapy+for+Post-Traumatic+Stress+Disorder/27067800.html <p align="justify">VANCOUVER, British Columbia, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("<strong>Optimi</strong>" or the "<strong>Company</strong>"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, announces plans to initiate a Health Canada-authorized Phase 3 clinical trial evaluating MDMA (3,4-methylenedioxymethamphetamine)-assisted therapy for individuals with post-traumatic stress disorder ("<strong>PTSD</strong>"). The trial is expected to begin in 2027.</p> <p align="justify">The Phase 3 clinical trial is intended to enroll up to 100 participants across multiple sites in Canada, with enrollment focused on veterans and current or former frontline workers, including military, police, paramedics, firefighters http://www.streetinsider.com/Press+Releases/Optimi+Health+Expands+Clinical+Program+with+Phase+3+Trial+Evaluating+MDMA-Assisted+Therapy+for+Post-Traumatic+Stress+Disorder/27067800.html Wed, 16 Sep 2026 08:25:00 -0400 OPTH OPTI Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder http://www.streetinsider.com/Globe+Newswire/Optimi+Health+Expands+Clinical+Program+with+Phase+3+Trial+Evaluating+MDMA-Assisted+Therapy+for+Post-Traumatic+Stress+Disorder/27067800.html <p align="justify">VANCOUVER, British Columbia, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("<strong>Optimi</strong>" or the "<strong>Company</strong>"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, announces plans to initiate a Health Canada-authorized Phase 3 clinical trial evaluating MDMA (3,4-methylenedioxymethamphetamine)-assisted therapy for individuals with post-traumatic stress disorder ("<strong>PTSD</strong>"). The trial is expected to begin in 2027.</p> <p align="justify">The Phase 3 clinical trial is intended to enroll up to 100 participants across multiple sites in Canada, with enrollment focused on veterans and current or former frontline workers, including military, police, paramedics, firefighters http://www.streetinsider.com/Globe+Newswire/Optimi+Health+Expands+Clinical+Program+with+Phase+3+Trial+Evaluating+MDMA-Assisted+Therapy+for+Post-Traumatic+Stress+Disorder/27067800.html Wed, 16 Sep 2026 08:25:00 -0400 OPTH OPTI Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder http://www.streetinsider.com/Press+Releases/Optimi+Health+Expands+Clinical+Program+with+Phase+3+Trial+Evaluating+MDMA-Assisted+Therapy+for+Post-Traumatic+Stress+Disorder/27067800.html <p align="justify">VANCOUVER, British Columbia, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("<strong>Optimi</strong>" or the "<strong>Company</strong>"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, announces plans to initiate a Health Canada-authorized Phase 3 clinical trial evaluating MDMA (3,4-methylenedioxymethamphetamine)-assisted therapy for individuals with post-traumatic stress disorder ("<strong>PTSD</strong>"). The trial is expected to begin in 2027.</p> <p align="justify">The Phase 3 clinical trial is intended to enroll up to 100 participants across multiple sites in Canada, with enrollment focused on veterans and current or former frontline workers, including military, police, paramedics, firefighters http://www.streetinsider.com/Press+Releases/Optimi+Health+Expands+Clinical+Program+with+Phase+3+Trial+Evaluating+MDMA-Assisted+Therapy+for+Post-Traumatic+Stress+Disorder/27067800.html Wed, 16 Sep 2026 08:25:00 -0400 OPTH OPTI Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder http://www.streetinsider.com/Globe+Newswire/Optimi+Health+Expands+Clinical+Program+with+Phase+3+Trial+Evaluating+MDMA-Assisted+Therapy+for+Post-Traumatic+Stress+Disorder/27067800.html <p align="justify">VANCOUVER, British Columbia, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("<strong>Optimi</strong>" or the "<strong>Company</strong>"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, announces plans to initiate a Health Canada-authorized Phase 3 clinical trial evaluating MDMA (3,4-methylenedioxymethamphetamine)-assisted therapy for individuals with post-traumatic stress disorder ("<strong>PTSD</strong>"). The trial is expected to begin in 2027.</p> <p align="justify">The Phase 3 clinical trial is intended to enroll up to 100 participants across multiple sites in Canada, with enrollment focused on veterans and current or former frontline workers, including military, police, paramedics, firefighters http://www.streetinsider.com/Globe+Newswire/Optimi+Health+Expands+Clinical+Program+with+Phase+3+Trial+Evaluating+MDMA-Assisted+Therapy+for+Post-Traumatic+Stress+Disorder/27067800.html Wed, 16 Sep 2026 08:25:00 -0400 OPTH OPTI